DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Beta Drugs Limited — Outcome of Board Meeting

NSE 18 hrs ago·20 Jul 2026, 3:30 am

Beta Drugs

Beta Drugs Limited has informed the stock exchange that its board has approved the financial results for the period ending June 30, 2026. This announcement marks a key milestone for the company, as it provides the market with an official update on its financial performance and operational status during the specified quarter.

For investors, this update is important as it offers a snapshot of the company's current trajectory. The results will likely be scrutinized for any shifts in revenue, profitability, or operational efficiency, which are critical factors for assessing the company's health and future growth potential.

Investors should watch for the detailed release of these results, which will provide a deeper analysis of the company's performance. Market participants will be looking for guidance on future business prospects and any strategic shifts that may impact the stock's valuation.